Literature DB >> 19924534

Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease?

Linda A Feagins1, Byron L Cryer.   

Abstract

The safety of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with inflammatory bowel disease (IBD) remains unclear. This report discusses potential mechanisms whereby NSAIDs might exacerbate IBD and reviews the available clinical data on the role of NSAIDs in causing exacerbations of ulcerative colitis (UC) and Crohn's disease (CD).

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19924534     DOI： 10.1007/s10620-009-1042-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  37 in total

1.  Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study.

Authors:  J B Felder; B I Korelitz; R Rajapakse; S Schwarz; A P Horatagis; G Gleim
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

Review 2.  Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies.

Authors:  Fulvio D'Acquisto; Michael J May; Sankar Ghosh
Journal:  Mol Interv       Date:  2002-02

3.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

4.  Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.

Authors:  Uma Mahadevan; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

5.  Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat.

Authors:  S Somasundaram; G Sigthorsson; R J Simpson; J Watts; M Jacob; I A Tavares; S Rafi; A Roseth; R Foster; A B Price; J M Wrigglesworth; I Bjarnason
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

Review 6.  NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs.

Authors:  John L Wallace; Linda Vong
Journal:  Curr Opin Investig Drugs       Date:  2008-11

7.  The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease.

Authors:  Robin Matuk; Jonathan Crawford; Maria T Abreu; Stephan R Targan; Eric A Vasiliauskas; Konstantinos A Papadakis
Journal:  Inflamm Bowel Dis       Date:  2004-07       Impact factor: 5.325

8.  Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.

Authors:  Ken-Ichiro Tanaka; Shintaro Suemasu; Tomoaki Ishihara; Yuichi Tasaka; Yasuhiro Arai; Tohru Mizushima
Journal:  Eur J Pharmacol       Date:  2008-12-06       Impact factor: 4.432

Review 9.  Eicosanoids and the gastrointestinal tract.

Authors:  C E Eberhart; R N Dubois
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

10.  Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial.

Authors:  L Biancone; C Tosti; A Geremia; D Fina; C Petruzziello; S Emerenziani; F Pallone
Journal:  Aliment Pharmacol Ther       Date:  2004-04-01       Impact factor: 8.171
View more
  17 in total

1.  Regulation of interferon signaling in response to gut microbes by autophagy.

Authors:  Patricia K Martin; Ken Cadwell
Journal:  Gut Microbes       Date:  2019-05-23

2.  Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis.

Authors:  Masako Nakanishi; Christine Perret; Emmanuelle J Meuillet; Daniel W Rosenberg
Journal:  Carcinogenesis       Date:  2015-01-29       Impact factor: 4.944

3.  Narcotic use for inflammatory bowel disease and risk factors during hospitalization.

Authors:  Millie D Long; Edward L Barnes; Hans H Herfarth; Douglas A Drossman
Journal:  Inflamm Bowel Dis       Date:  2011-07-07       Impact factor: 5.325

Review 4.  Impact of environmental and dietary factors on the course of inflammatory bowel disease.

Authors:  Eduard Cabré; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

5.  Case-control study of factors that trigger inflammatory bowel disease flares.

Authors:  Linda A Feagins; Ramiz Iqbal; Stuart J Spechler
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

6.  Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease.

Authors:  Ana Gutiérrez; Pedro Zapater; Oriol Juanola; Laura Sempere; Marifé García; Raquel Laveda; Antonio Martínez; Michael Scharl; José M González-Navajas; José Such; Reiner Wiest; Gerhard Rogler; Rubén Francés
Journal:  Am J Gastroenterol       Date:  2016-02-23       Impact factor: 10.864

7.  Design and Synthesis of Nanofibers of Self-assembled de novo Glycoconjugates towards Mucosal Lining Restoration and Anti-Inflammatory Drug Delivery.

Authors:  Jie Zhou; Michael O'Keeffe; Gongxian Liao; Fan Zhao; Cox Terhorst; Bing Xu
Journal:  Tetrahedron       Date:  2016-07-26       Impact factor: 2.457

8.  Managing pain in inflammatory bowel disease.

Authors:  Michael J Docherty; R Carter W Jones; Mark S Wallace
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-09

Review 9.  [DGRh recommendations for the implementation of current security aspects in the NSAID treatment of musculoskeletal pain].

Authors:  W W Bolten; K Krüger; S Reiter-Niesert; D O Stichtenoth
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

Review 10.  A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies.

Authors:  George J DeMarco; Elizabeth A Nunamaker
Journal:  Comp Med       Date:  2019-12-20       Impact factor: 0.982
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.